Bristol-Myers Squibb (NY:BMY)

59.71 +0.63 (+1.07%)

Official Closing Price Updated: 7:00 PM EDT, Mar 16, 2026 Add to My Watchlist

Price and Volume

Volume	8,436,525
Open	59.49
Bid (Size)	59.60 (300)
Ask (Size)	59.71 (400)
Prev. Close	59.08
Today's Range	58.87 - 59.80
52wk Range	42.52 - 62.89
Shares Outstanding	2,222,113,553
Dividend Yield	4.22%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026

Today 11:58 EDT

Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors...

Via MarketMinute

1 ETF That Could Turn $100 Per Month Into $67,380 ↗

March 15, 2026

How does solid growth -- plus a 3.3% dividend yield sound?

Via The Motley Fool

Performance

YTD	+11.7%	+11.7%
1 Month	-1.7%	-1.7%
3 Month	+10.0%	+10.0%
6 Month	+28.8%	+28.8%
1 Year	-0.5%	-0.5%

More News

Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors ↗

March 13, 2026

Via Chartmill

1 S&P 500 Stock Worth Your Attention and 2 We Question

March 12, 2026

Via StockStory

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

Via MarketMinute

3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗

March 10, 2026

Via The Motley Fool

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

March 09, 2026

From Bristol Myers Squibb

Via Business Wire

Why Bristol Myers Squibb Stock Crushed it in February ↗

March 08, 2026

Via The Motley Fool

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

March 06, 2026

From Bristol Myers Squibb

Via Business Wire

2 Top Healthcare Dividend Stocks to Buy and Hold Forever ↗

March 05, 2026

Via The Motley Fool

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2026

Via StockStory

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

Via Stocktwits

Bristol Myers Squibb Announces Dividend

March 02, 2026

From Bristol Myers Squibb

Via Business Wire

How to Spot Winning Innovation ↗

March 02, 2026

Via The Motley Fool

FourWorld Takes a Major Swing on Sable Offshore (SOC), Buying 8 Million Shares ↗

March 02, 2026

Via The Motley Fool

Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement ↗

February 28, 2026

Via The Motley Fool

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

Via MarketMinute

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

February 26, 2026

From Bristol Myers Squibb

Via Business Wire

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

Via MarketMinute

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

Via FinancialNewsMedia

3 Reasons to Avoid BMY and 1 Stock to Buy Instead

February 23, 2026

Via StockStory

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

Via MarketMinute

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm

February 22, 2026

Via StockStory

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?

Yes, Bristol-Myers Squibb is publicly traded.

What exchange does Bristol-Myers Squibb trade on?

Bristol-Myers Squibb trades on the New York Stock Exchange

What is the ticker symbol for Bristol-Myers Squibb?

The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange

What is the current price of Bristol-Myers Squibb?

The current price of Bristol-Myers Squibb is 59.71

When was Bristol-Myers Squibb last traded?

The last trade of Bristol-Myers Squibb was at 03/16/26 07:00 PM ET

What is the market capitalization of Bristol-Myers Squibb?

The market capitalization of Bristol-Myers Squibb is 132.68B

How many shares of Bristol-Myers Squibb are outstanding?

Bristol-Myers Squibb has 133B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.